Previous 10 | Next 10 |
2023-10-06 06:55:38 ET Related stories Aehr Test Systems (AEHR) Q1 2024 Earnings Call Transcript Exxon Mobil: Just An All Around Solid Company Aehr Test Systems: SiC, GaN And Optical On-Chip Customers Drive Increasing Revenues Exxon close to buying Pioneer Na...
2023-10-05 07:06:31 ET More on Nanobiotix Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript Nanobiotix: At A Crucial Juncture For Data Nanobiotix: French Radiation Enhancer Developer With A Major JNJ Deal Biggest stock movers today: Icahn Enterprises, S...
Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56) Consistently high injected-lesion overall response rate of 81.8% and complete response rate of 63.6% in the evaluable p...
PARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities ...
Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains feasible with a tolerable safety profile in 15 patients As of t...
2023-09-27 10:52:06 ET Nanobiotix S.A. (NBTX) Q2 2023 Earnings Conference Call September 27, 2023 08:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder & CEO Bart Van Rhijn - CFO Conference Call Participants Lucy Codringt...
2023-09-26 16:31:29 ET More on Nanobiotix Seeking Alpha’s Quant Rating on Nanobiotix Historical earnings data for Nanobiotix Financial information for Nanobiotix Nanobiotix: At A Crucial Juncture For Data Nanobiotix: French Radiation Enhancer D...
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Upfront payment and first equity tranche received by Nanobiotix post H1 2023 from agreement with Janssen extends ...
Nanobiotix S.A. (NBTX) is expected to report for Q2 2023 Wal-mart de Mexico S A B de C V ADR (WMMVY) is expected to report for Q2 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q1 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-...
Nanobiotix S.A. (NBTX) is expected to report for Q2 2023
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...